Background: The treatment of traumatised refugees is one of the areas within the field of psychiatry with the weakest evidence for the different types of treatment. This is a problem for both patients and doctors as well as for society. The treatment of choice today for Post Traumatic Stress disorder (PTSD) is antidepressants from the subgroup of Selektive Serotonin Reuptake Inhibitors (SSRI), among these the drug Sertraline. The evidence for the use of these drugs as treatment for chronically complex PTSD in traumatised refugees is however very limited and a large part of the group is estimated to be insufficiently treated with this type of medicine. Venlafaxine is an antidepressant from the subgroup of dual action product which means that is works on several pathways in the brain. Among others it influences the area in the brain that is responsible for the enhanced anxiety and hyperarousal experienced by traumatised refugees and which is found to be enlarged among patients suffering from PTSD. All together there is not sufficient evidence to conclude which type of medical and psychological treatment that is most efficient when it comes to the treatment of traumatised refugees. Also there is a lack of studies which examines social functioning and the relation between psychosocial resources and outcome from treatment. Furthermore there is a lack of knowledge of predictors of treatment outcome for the individual patients. This study seeks to produce some of this evidence. Method: This study is expected to include approximately 150 patients randomised into two different groups. The patients are treated with Setraline or Venlafaxine depending on the group the randomised to. Patients in both groups are getting the same version of manual based Cognitive Behavioural Therapy that is specially adapted to this group of patients. The treatment period is 6-7 month. The trial endpoints are PTSD-and depression symptoms and social functioning all measured on internationally validated ratings scales. Furthermore the study will examine the relation between expected outcome of treatment from a range of predictors and the actual treatment results for the individual patient. Results: Altogether this study will bring forward new standards for clinical evaluation and treatment of traumatised refugees and the results are expected to be used in reference programmes/clinical guidelines.
Please see the summary above
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
207
Tablets, once a day, max 375 mg day (maximal recommended dose)
Tablets, once a day, maximum 200 mg/day (maximum required dose)
Competence Center for Transcultural Psychiatry
Gentofte Municipality, Denmark
Harvard Trauma Questionnaire (HTQ)
Self administered Rating Scale
Time frame: Change from baseline after aprox. 6 months treatment
Hopkins Symptom Check List (HSCL-25)
Time frame: Change from baseline after aprox. 6 months treatment
Social Adjustment Scale Self Report (SAS-SR) short version
Time frame: Change from baseline after aprox. 6 months treatment
Hamilton Depresssion Scale (17 items)
Time frame: Change from baseline after aprox. 6 months treatment
Hamilton Anxiety Scale (14 items)
Time frame: Change from baseline after aprox. 6 months treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.